• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA

    11/14/25 5:29:17 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $ABVX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 2)


    Abivax SA

    (Name of Issuer)


    Ordinary Shares, nominal value 0.01 euro per share

    (Title of Class of Securities)


    00370M103

    (CUSIP Number)


    09/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox not checked   Rule 13d-1(b)
    Checkbox checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners III, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    576,729.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    576,729.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    576,729.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    VHCP Co-Investment Holdings III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    576,729.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    576,729.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    576,729.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    Venrock Healthcare Capital Partners EG, L.P.
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    576,729.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    576,729.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    576,729.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    PN


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    VHCP Management III, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    576,729.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    576,729.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    576,729.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    VHCP Management EG, LLC
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    576,729.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    576,729.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    576,729.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    OO


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    Nimish Shah
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    576,729.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    576,729.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    576,729.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    CUSIP No.
    00370M103


    1Names of Reporting Persons

    Bong Y. Koh
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    UNITED STATES
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    576,729.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    576,729.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    576,729.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    0.8 %
    12Type of Reporting Person (See Instructions)

    IN


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Abivax SA
    (b)Address of issuer's principal executive offices:

    7-11 boulevard Haussmann, Paris, I0, 76009 .
    Item 2. 
    (a)Name of person filing:

    The names of the persons filing this report (collectively, the "Reporting Persons") are: Venrock Healthcare Capital Partners III, L.P. ("VHCP III") VHCP Co-Investment Holdings III, LLC ("VHCP Co-Investment III") Venrock Healthcare Capital Partners EG, L.P. ("VHCP EG") VHCP Management III, LLC ("VHCP Management III") VHCP Management EG, LLC ("VHCP Management EG") Nimish Shah ("Shah") Bong Koh ("Koh") The Reporting Persons are members of a group for the purposes of this Schedule 13G/A.
    (b)Address or principal business office or, if none, residence:

    New York Office: 7 Bryant Park, 23rd Floor New York, NY 10018 Palo Alto Office: 3340 Hillview Avenue Palo Alto, CA 94304
    (c)Citizenship:

    All of the entities were organized in Delaware. Shah and Koh are both United States citizens.
    (d)Title of class of securities:

    Ordinary Shares, nominal value 0.01 euro per share
    (e)CUSIP No.:

    00370M103
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox not checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    There is no CUSIP number assigned to the ordinary shares. CUSIP number 00370M103 has been assigned to the American Depositary Shares ("ADSs") of the Issuer. Each ADS represents one ordinary share. Row 9 of each Reporting Person's cover page to this Schedule 13G/A sets forth the aggregate number of ordinary shares of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. The Reporting Persons' ownership of the Issuer's securities consists of (i) 151,622 ordinary shares in the form of 151,622 ADSs directly held by VHCP III; (ii) 15,167 ordinary shares in the form of 15,167 ADSs directly held by VHCP Co-Investment III; and (iii) 409,940 ordinary shares in the form of 409,940 ADSs directly held by VHCP EG. VHCP Management III is the general partner of VHCP III and the manager of VHCP Co-Investment III. VHCP Management EG is the general partner of VHCP EG. Messrs. Shah and Koh are the voting members of VHCP Management III and VHCP Management EG.
    (b)Percent of class:

    Row 11 of each Reporting Person's cover page to this Schedule 13G/A sets forth the percentages of the ordinary shares of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference. Such percentage is based upon 73,574,749 ordinary shares of the Issuer outstanding as July 28, 2025, as reported in the Issuer's prospectus supplement dated July 23, 2025 filed with the Securities and Exchange Commission (the "SEC") on July 24, 2025.
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    Row 5 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

     (ii) Shared power to vote or to direct the vote:

    Row 6 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to vote or to direct the vote of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

     (iii) Sole power to dispose or to direct the disposition of:

    Row 7 of each Reporting Person's cover page to this Schedule 13G/A sets forth the sole power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

     (iv) Shared power to dispose or to direct the disposition of:

    Row 8 of each Reporting Person's cover page to this Schedule 13G/A sets forth the shared power to dispose or to direct the disposition of securities of the Issuer beneficially owned by such Reporting Person as of September 30, 2025 and is incorporated by reference.

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Venrock Healthcare Capital Partners III, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management II, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:11/14/2025
     
    VHCP Co-Investment Holdings III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management III, LLC, its Manager, By Sherman G. Souther, Authorized Signatory
    Date:11/14/2025
     
    Venrock Healthcare Capital Partners EG, L.P.
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By VHCP Management EG, LLC, its General Partner, By Sherman G. Souther, Authorized Signatory
    Date:11/14/2025
     
    VHCP Management III, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:11/14/2025
     
    VHCP Management EG, LLC
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Authorized Signatory
    Date:11/14/2025
     
    Nimish Shah
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:11/14/2025
     
    Bong Y. Koh
     
    Signature:/s/ Sherman G. Souther
    Name/Title:By Sherman G. Souther, Attorney-in-fact
    Date:11/14/2025
    Exhibit Information

    Exhibit 24.1 Power of Attorney for Nimish Shah (incorporated by reference to Exhibit B to Schedule 13G filed November 22, 2023) Exhibit 24.2 Power of Attorney for Bong Koh (incorporated by reference to Exhibit C to Schedule 13G filed on November 22, 2023) Exhibit 99.1 Joint Filing Agreement (incorporated by reference to Exhibit A to Schedule 13G filed on November 22, 2023)

    Get the next $ABVX alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ABVX

    DatePrice TargetRatingAnalyst
    11/24/2025Buy
    Truist
    11/6/2025$176.00Outperform
    Wolfe Research
    10/13/2025$142.00Overweight
    Barclays
    7/23/2025$71.00Equal-Weight → Overweight
    Morgan Stanley
    3/20/2025$12.00Equal-Weight
    Morgan Stanley
    12/4/2024$33.00Mkt Outperform
    JMP Securities
    7/29/2024$48.00Buy
    Laidlaw
    5/20/2024$43.00Buy
    BTIG Research
    More analyst ratings

    $ABVX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis

    Abivax Announces Patient-Reported Outcomes Data from the Phase 3 ABTECT Induction Trials of Obefazimod, Demonstrating Significant Improvements in Quality of Life for Patients with Moderate-to-Severely Active Ulcerative Colitis Improvements across all patient reported outcomes (PROs) were observed from baseline to Week 8 in all PRO instruments utilized in the ABTECT induction trials evaluating bowel urgency, sleep interruption, fatigue, quality of life, and work productivity for both 50mg and 25mg once-daily obefazimod.At week 8 in the ABTECT 1 & 2 trials, 37% of patients taking once daily 50mg obefazimod reported no bowel urgency (BU) compared to 18.1% of patients in the placebo group (18.

    11/3/25 4:05:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of advanced therapies including JAK inhibitors in the pooled ABTECT 1 & 2 Trials (w/AT-IR pbo adjusted D 10%, p=0.0009†; w/o AT-IR pbo adjusted D 22%, p<0.0001†)50mg obefazimod demonstrated clinically me

    10/6/25 4:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefazimod treatment was well tolerated with no new safety signals identified for both the 25mg and 50mg doses Abivax to present a second late-breaking abstract on October 6. Management to host a conferen

    10/5/25 11:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Truist initiated coverage on Abivax SA

    Truist initiated coverage of Abivax SA with a rating of Buy

    11/24/25 8:30:31 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Wolfe Research initiated coverage on Abivax SA with a new price target

    Wolfe Research initiated coverage of Abivax SA with a rating of Outperform and set a new price target of $176.00

    11/6/25 8:47:47 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Barclays initiated coverage on Abivax SA with a new price target

    Barclays initiated coverage of Abivax SA with a rating of Overweight and set a new price target of $142.00

    10/13/25 8:51:16 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    SEC Filings

    View All

    Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA

    SCHEDULE 13G/A - Abivax S.A. (0001956827) (Subject)

    11/14/25 5:29:17 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Abivax SA

    SCHEDULE 13G/A - Abivax S.A. (0001956827) (Subject)

    11/14/25 4:22:54 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13D/A filed by Abivax SA

    SCHEDULE 13D/A - Abivax S.A. (0001956827) (Subject)

    10/30/25 4:08:59 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Leadership Updates

    Live Leadership Updates

    View All

    Abivax Announces Results of its June 6, 2025 Annual General Meeting

    Abivax Announces Results of its June 6, 2025 Annual General Meeting PARIS, France, June 11, 2025, 10:00 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, held its annual general meeting of shareholders on June 6, 2025 (the "General Meeting"), which was chaired by Ms. Sylvie Grégoire Chairman of the Board of Directors of Abivax ("Board"). The shareholders have adopted all the resolutions proposed by the Board, and particularly the financial statements for the 2024 fina

    6/11/25 4:00:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors

    Abivax Announces Appointment of Dominik Höchli, MD to Board of Directors Industry veteran brings deep immunology expertise ahead of key Phase 3 data readout in ulcerative colitis expected in Q3 2025 PARIS, France, April 22, 2025, 10:00 pm CEST – Abivax SA (PARIS:FR, NASDAQ:ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Dominik Höchli, MD to the Board of Directors of Abivax, effective immediately. Dr. Höchli brings over two decades of leadership experience in

    4/22/25 4:00:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax

    Abivax Announces Former Prometheus COO, Mark Stenhouse, Appointed as Board Observer & Advisor to Abivax PARIS, France, November 13, 2024, 10:00 pm CET – Abivax SA (Euronext Paris and Nasdaq: ABVX) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced the appointment of Mark Stenhouse as Board Observer and Advisor to Abivax. Mr. Stenhouse brings more than 30 years of experience in the biopharma industry. Most recently, he served as Chief Operating Officer of Prometheus Biosciences, a biotechn

    11/13/24 4:01:00 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Abivax SA

    SC 13G/A - Abivax S.A. (0001956827) (Subject)

    11/14/24 9:09:55 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G filed by Abivax SA

    SC 13G - Abivax S.A. (0001956827) (Subject)

    4/19/24 7:09:50 PM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ABVX
    Financials

    Live finance-specific insights

    View All

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Induction Trial Results in Participants With and Without Prior Inadequate Response to Advanced Therapies 50 mg dose of once-daily obefazimod achieved clinically meaningful improvements, across all endpoints, regardless of prior inadequate response to advanced therapies (AT-IR) 50mg dose demonstrated clinically meaningful improvements in clinical remission in participants with and without prior inadequate response to up to 4+ lines of advanced therapies including JAK inhibitors in the pooled ABTECT 1 & 2 Trials (w/AT-IR pbo adjusted D 10%, p=0.0009†; w/o AT-IR pbo adjusted D 22%, p<0.0001†)50mg obefazimod demonstrated clinically me

    10/6/25 4:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data

    Abivax Announces Late-Breaking Presentation of 8-Week ABTECT Trial Results with Updated Safety Data 50 mg once-daily dose of obefazimod led to a pooled 16.4% (p<0.0001) placebo-adjusted clinical remission rate at Week 8; met primary and all key secondary endpoints in both ABTECT 1 and ABTECT 2ABTECT trials enrolled refractory patient population with 47% of participants having prior inadequate response to advanced therapy, among whom 21% had prior inadequate response to JAK inhibitor therapyObefazimod treatment was well tolerated with no new safety signals identified for both the 25mg and 50mg doses Abivax to present a second late-breaking abstract on October 6. Management to host a conferen

    10/5/25 11:00:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review

    Abivax to Join CAC Mid 60 and SBF 120 Indices Following Euronext Paris Annual Review PARIS, France, September 12, 2025, 5:45 p.m. CEST – Abivax SA (PARIS:FR) ("Abivax" or the "Company"), a clinical-stage biotechnology company focused on developing therapeutics that harness the body's natural regulatory mechanisms to modulate the inflammatory response in patients with chronic inflammatory diseases, announces today that following the annual review of the Euronext Paris indices on September 11, 2025, the Scientific Council of the Indices has decided to admit Abivax to the CAC Mid 60 and SBF 120 indices. This decision will take effect on Friday, September 19, 2025, after market close. The CAC

    9/12/25 11:45:00 AM ET
    $ABVX
    Biotechnology: Pharmaceutical Preparations
    Health Care